ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,172.40
-1.16%
S&P ASX All Technology
3,708.30
-1.86%
Brent Oil
73.045
0.00%
US Dollar vs AUD
1.61135
0.00%
Bitcoin
85,456.43
1.29%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Immutep Ltd (IMMP) Share Price

Immutep Ltd

Immutep Ltd (IMMP)

NASDAQ
1.93
0.03
(1.58%)
Closed 01 March 8:00AM
Delayed by 15 minutes
1.93
0.00
(0.00%)
After Hours: 9:56AM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
1.93
Bid
1.87
Offer
1.97
Volume
118,807
1.87 Day's Range 1.94
0.00 52 Week Range 0.00
Market Cap
280.732M
Previous Close
1.90
Open
1.87
Last Trade
3
@
2
Last Trade Time
Financial Volume
US$ 226,318
VWAP
1.9049
Average Volume (3m)
-
Shares Outstanding
145,456,785
Dividend Yield
-
PE Ratio
-1.02
Earnings Per Share (EPS)
-0.29
Revenue
-
Net Profit
-42.72M

About Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.immutep.com
Headquarters
Sydney, New South Wales, Aus
Founded
-
Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was US$1.90. Over the last year, Immutep shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Immutep currently has 145,456,785 shares in issue. The market capitalisation of Immutep is US$276.37 million. Immutep has a price to earnings ratio (PE ratio) of -1.02.

Ask ADVFN Intelligence (AI)

IMMP Latest News

More News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
27 February 2025
IMMP (1.58%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
03 February 2025
IMMP (1.58%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
13 December 2024
IMMP (1.58%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
11 December 2024
IMMP (1.58%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

IMMP - Frequently Asked Questions (FAQ)

What is the current Immutep share price?
The current share price of Immutep is US$ 1.93
How many Immutep shares are in issue?
Immutep has 145,456,785 shares in issue
What is the market cap of Immutep?
The market capitalisation of Immutep is USD 276.37M
What is the 1 year trading range for Immutep share price?
Immutep has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Immutep?
The price to earnings ratio of Immutep is -1.02
What is the reporting currency for Immutep?
Immutep reports financial results in AUD
What is the latest annual profit for Immutep?
The latest annual profit of Immutep is AUD -42.72M
What is the registered address of Immutep?
The registered address for Immutep is LEVEL 12, 95 PITT STREET, SYDNEY, NEW SOUTH WALES, 2000
What is the Immutep website address?
The website address for Immutep is www.immutep.com
Which industry sector does Immutep operate in?
Immutep operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
STAKSTAK Inc
US$ 3.97
(156.13%)
173.35k
ORGOOrganogenesis Holdings Inc
US$ 6.21
(102.28%)
58.69M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
192.48M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
136.35M
ARBBARB IOT Group Ltd
US$ 0.6635
(38.23%)
58.86M
NVNINVNI Group Ltd
US$ 0.99
(-50.50%)
72.78M
SPGCSacks Parente Golf Inc
US$ 0.2085
(-48.65%)
58.2M
ADGMAdagio Medical Holdings Inc
US$ 0.8081
(-47.53%)
756.76k
PRAXPraxis Precision Medicines Inc
US$ 38.60
(-40.64%)
3.2M
SAGSAG Holdings Ltd
US$ 1.19
(-38.97%)
789.86k
NVDANVIDIA Corporation
US$ 124.92
(3.97%)
389.46M
TRNRInteractive Strength Inc
US$ 2.57
(67.97%)
193.54M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 13.44
(7.78%)
154.44M
PMAXPowell Max Ltd
US$ 0.511
(43.54%)
137.17M
LCIDLucid Group Inc
US$ 2.22
(-0.45%)
136.17M

IMMP Discussion

View Posts
Monksdream Monksdream 6 months ago
IMMP 10 day hourly
👍️0
Monksdream Monksdream 7 months ago
IMMP under $2
👍️0
Vector2112 Vector2112 7 months ago
Refinitiv Logo
As of 06/27/2024

SellUnderperformHoldOutperformSelected Value:Buy
Refinitiv Stock Reports Plus
Refinitiv maintains a current price target of $8.64 for IMMP.
👍️0
glenn1919 glenn1919 8 months ago
IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 8 months ago
IMMP under $2
👍️0
Monksdream Monksdream 10 months ago
IMMP under $3
👍️0
Monksdream Monksdream 1 year ago
IMMP under $2
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
strong
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
strong
👍️0
The Night Stalker The Night Stalker 2 years ago
watching
👍️0
The Night Stalker The Night Stalker 2 years ago
watching
👍️0
The Night Stalker The Night Stalker 2 years ago
dip
👍️0
The Night Stalker The Night Stalker 2 years ago
dip
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
im in my bio DRMA, one at a time


RIGL rip for more
👍️0
The Night Stalker The Night Stalker 2 years ago
beast
👍️0
DewDiligence DewDiligence 2 years ago
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
Invest-in-America Invest-in-America 2 years ago
IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

👍️0
stocks2watch stocks2watch 3 years ago
Going to move up
👍️0
make it happen make it happen 4 years ago
It's cool covered most average was $3.68
👍️0
calahan67 calahan67 4 years ago
I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
👍️0
make it happen make it happen 4 years ago
More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500

Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94

Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M
👍️0
sgunderbarth sgunderbarth 4 years ago
IMMP Interesting action....
👍️0
ClayTrader ClayTrader 4 years ago
* * $IMMP Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
make it happen make it happen 4 years ago
Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 4 years ago
Had R/S a couple years ago and was $0.53 about a year ago
👍️0
make it happen make it happen 4 years ago
Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 4 years ago
I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
👍️0
reverse_long reverse_long 4 years ago
IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
👍️0
calahan67 calahan67 4 years ago
This is the real deal folks
👍️0
ClayTrader ClayTrader 4 years ago
* * $IMMP Video Chart 03-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 4 years ago
IMMP up on BMY's LAG-3 coattails: #msg-162784750.
👍️0
calahan67 calahan67 4 years ago
And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
👍️0
calahan67 calahan67 4 years ago
Up huge on no news a great big sleeper imo
👍️0
calahan67 calahan67 4 years ago
Looks like accumulation is beginning a slow churn higher
👍️0
everything everything 4 years ago
Interesting company, looks to be in reversal but dip opportunity may be in the works.
👍️0
akamaii akamaii 4 years ago
Like it here
👍️0
lecorb lecorb 4 years ago
$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
👍️0

Your Recent History

NASDAQ
IMMP
Immutep
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads